Mike Hollan

Company leadership urged members and employees to stay safe and follow evacuation orders.

Dan Monahan will serve in the role as the drug goes through Phase III trials.

‘Shape Shifting’ is a creator-led series that focuses on the scientific and cultural impact of GLP-1s.

The campaign will include patient stories, education resources, and is being held in partnership with the Glaucoma Research Foundation.

Mary Kosinski joined the firm as global managing director for the sector, along with other leadership additions.

Both companies have produced AI-powered technology that improves data collection and analysis.

Deloitte’s US life sciences sector leader discusses the trends he believes will have the most impact in 2025.

Pavone discusses how these methods can be used to combat a lack of diversity in clinical trials.

The campaign is focused on the drug’s ability to fight hunger cravings.

The partnership will allow CMI to use Anoki’s AI technology to provide targeted advertising.

GlobalData’s new findings show that the Zepbound may become the top WLM in the coming year.

Artificial Intelligence took the industry by storm this year, but how is actually being implemented?

GLP-1s continue to dominate the market, but can pharma keep up with the demand?

Point of care messaging and AI resulted in more targeted campaigns over the past year.

New technologies are creating more efficient ways for pharma companies to work directly with consumers.

Pharm Exec covered key players in the industry over the past year.

In the third part of this roundtable discussion, experts discuss the issues with data that AI must overcome.

Sermo’s survey also reveals some troubling aspects about the public’s relationship with these medications.

The Upscript Health CEO discusses trends in telehealth for the coming year.

The molecule is an investigational pre-clinical oral GLP-1 receptor agonist.

PharmaLex’s chief strategy officer discusses strategies to improve monetization for these drugs.

Margaret Keegan, the new CEO of Precision Medicine Group, is eager to elevate the profile of the expert-rich service provider and build it into an industry leader in next-gen drug development and commercialization support.

Unleashed demand over the past year characterizes the M&A picture in pharma.

Regulatory, technological, and other factors are set to have a significant impact in the coming year.

This will bring Nimble’s psoriasis and inflammatory bowel disease treatment under AbbVie’s pipeline.

With the Inflation Reduction Act now in flux, how will the government and industry respond?

The swell of AI-powered digital platforms puts future decision-making under the spotlight.

Eli Lilly and Boehringer Ingelheim are also participating in the campaign, which will feature a float in the 2024 Rose Parade.

In the second part of this roundtable discussion, experts discuss how the industry is handling AI in the marketing space.

The two organizations are promoting education and the importance of screenings.